Last update 08 May 2025

CD20 x VEGFR2 x EGFR x CD19

Basic Info

Related Targets
CD20VEGFR2EGFR[+1]

Related

1
Drugs associated with CD20 x VEGFR2 x EGFR x CD19
Diakine-DK210
Target
CD19 x CD20 x EGFR x VEGFR2
Mechanism
CD19 inhibitors [+3]
Active Org.
Deka Biosciences, Inc.
Originator Org.
Deka Biosciences, Inc.
Active Indication
Colorectal Cancer [+6]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with CD20 x VEGFR2 x EGFR x CD19
NCT05704985
/ RecruitingPhase 1
Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
100 Clinical Results associated with CD20 x VEGFR2 x EGFR x CD19
Login to view more data
100 Translational Medicine associated with CD20 x VEGFR2 x EGFR x CD19
Login to view more data
0 Patents (Medical) associated with CD20 x VEGFR2 x EGFR x CD19
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free